Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma.
Experience of scintigraphic detection of bone lesion and active bone marrow involvement of multiple myeloma, especially with sestamibi and FDG-PET scans is in evolution. We report a case of intense sestamibi uptake in bone marrow correlating with the extent of the disease, while FDG-PET scans showed activity only in areas of active disease progression associated with pain. Technetium-99m-sestamibi appears to indicate the extent of the disease, while [18F]FDG-PET scans show sites of active tumor proliferation and may be useful in directing local therapy such as radiation.
el-Shirbiny
A M
AM
Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Yeung
H
H
Imbriaco
M
M
Michaeli
J
J
Macapinlac
H
H
Larson
S M
SM
D000368:Aged; D003847:Deoxyglucose / Q000031:analogs & derivatives*; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals; D017256:Technetium Tc 99m Sestamibi; D014055:Tomography, Emission-Computed
D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D017256:Technetium Tc 99m Sestamibi; D003847:Deoxyglucose